Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.636 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C4=CC=CC5=C4C=NN5)N6CCOCC6)CC1
InChI
InChIKey=LHNIIDJUOCFXAP-UHFFFAOYSA-N
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pictilisib is an oral potent inhibitor of class I PI3K with nanomolar activities against p110alpha, p110beta, p110delta, and p110gamma. The drug was developed for the treatment of solid tumors and reached phase II in patients with breast cancer and lung carcinoma, however its development was terminated.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.52 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25370471 |
330 mg single, oral dose: 330 mg route of administration: Oral experiment type: SINGLE co-administered: |
PICTILISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19.4 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25370471 |
330 mg single, oral dose: 330 mg route of administration: Oral experiment type: SINGLE co-administered: |
PICTILISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25370471 |
330 mg single, oral dose: 330 mg route of administration: Oral experiment type: SINGLE co-administered: |
PICTILISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015-06 |
|
| The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. | 2014-01-16 |
|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013-11 |
|
| Single cell network profiling assay in bladder cancer. | 2013-04 |
|
| A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. | 2013-02-01 |
|
| Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. | 2013-02-01 |
|
| GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. | 2013-02-01 |
|
| Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. | 2013-01-17 |
|
| Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. | 2013-01 |
|
| Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. | 2012-12-15 |
|
| Diacylglycerol kinase δ1 transiently translocates to the plasma membrane in response to high glucose. | 2012-12 |
|
| Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. | 2012-10 |
|
| Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases. | 2012-10 |
|
| Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. | 2012-08 |
|
| Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. | 2012-08 |
|
| GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. | 2012-07-15 |
|
| Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. | 2012-07 |
|
| Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. | 2012-05-17 |
|
| Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. | 2012-05 |
|
| The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. | 2012-04-10 |
|
| Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma. | 2012-02 |
|
| The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. | 2012-02 |
|
| Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. | 2012-01-01 |
|
| PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells. | 2012 |
|
| Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. | 2012 |
|
| The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells. | 2012 |
|
| GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. | 2011-12 |
|
| Comprehensive analysis of kinase inhibitor selectivity. | 2011-10-30 |
|
| GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. | 2011-10-01 |
|
| Essential role of Stat3 in PI3K-induced oncogenic transformation. | 2011-08-09 |
|
| Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. | 2011-03-29 |
|
| Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. | 2011-01-28 |
|
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010-11-24 |
|
| Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption. | 2010-10 |
|
| Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. | 2010-09-08 |
|
| Targeting a common collaborator in cancer development. | 2010-09-08 |
|
| Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. | 2010-09 |
|
| Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. | 2010-09 |
|
| PIKing the right patient. | 2010-07-15 |
|
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. | 2010-07-15 |
|
| Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. | 2010-04 |
|
| Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. | 2010-03-26 |
|
| Drugging the PI3 kinome: from chemical tools to drugs in the clinic. | 2010-03-15 |
|
| Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. | 2010-02-01 |
|
| Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. | 2009-07 |
|
| Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. | 2009-06-15 |
|
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. | 2009-05-05 |
|
| High-throughput screening compatible cell-based assay for interrogating activated notch signaling. | 2009-02 |
|
| The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . | 2008-09-25 |
Sample Use Guides
Patients with breast cancer receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with 260 mg pictilisib (daily on days 1-5 every week).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:16:48 GMT 2025
by
admin
on
Mon Mar 31 20:16:48 GMT 2025
|
| Record UNII |
ICY00EMP8P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40241930
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
DB11663
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
ICY00EMP8P
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
9417
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL521851
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
100000175029
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
SUB120770
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
m11673
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
957054-30-7
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
C165479
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
17755052
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
YY-114
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
